191 related articles for article (PubMed ID: 22080337)
1. Identifying specific chemotherapeutic agents in Medicare data: a validation study.
Lund JL; Stürmer T; Harlan LC; Sanoff HK; Sandler RS; Brookhart MA; Warren JL
Med Care; 2013 May; 51(5):e27-34. PubMed ID: 22080337
[TBL] [Abstract][Full Text] [Related]
2. Utility of the SEER-Medicare data to identify chemotherapy use.
Warren JL; Harlan LC; Fahey A; Virnig BA; Freeman JL; Klabunde CN; Cooper GS; Knopf KB
Med Care; 2002 Aug; 40(8 Suppl):IV-55-61. PubMed ID: 12187169
[TBL] [Abstract][Full Text] [Related]
3. Construct validity of medicare chemotherapy claims: the case of 5FU.
Lamont EB; Lauderdale DS; Schilsky RL; Christakis NA
Med Care; 2002 Mar; 40(3):201-11. PubMed ID: 11880793
[TBL] [Abstract][Full Text] [Related]
4. Comparison of SEER Treatment Data With Medicare Claims.
Noone AM; Lund JL; Mariotto A; Cronin K; McNeel T; Deapen D; Warren JL
Med Care; 2016 Sep; 54(9):e55-64. PubMed ID: 24638121
[TBL] [Abstract][Full Text] [Related]
5. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage.
Chawla N; Yabroff KR; Mariotto A; McNeel TS; Schrag D; Warren JL
Ann Epidemiol; 2014 Sep; 24(9):666-72, 672.e1-2. PubMed ID: 25066409
[TBL] [Abstract][Full Text] [Related]
6. Validation of electronic data on chemotherapy and hormone therapy use in HMOs.
Ritzwoller DP; Carroll N; Delate T; O'Keeffe-Rossetti M; Fishman PA; Loggers ET; Aiello Bowles EJ; Elston-Lafata J; Hornbrook MC
Med Care; 2013 Oct; 51(10):e67-73. PubMed ID: 22531648
[TBL] [Abstract][Full Text] [Related]
7. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.
Hershman DL; Buono DL; Malin J; McBride R; Tsai WY; Neugut AI
J Natl Cancer Inst; 2009 Dec; 101(23):1633-41. PubMed ID: 19903808
[TBL] [Abstract][Full Text] [Related]
8. Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study.
Fleming ST; Kimmick GG; Sabatino SA; Cress RD; Wu XC; Trentham-Dietz A; Huang B; Hwang W; Liff JM;
Ann Epidemiol; 2012 Nov; 22(11):807-13. PubMed ID: 22948184
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of three algorithms to identify incident breast cancer in Medicare claims data.
Gold HT; Do HT
Health Serv Res; 2007 Oct; 42(5):2056-69. PubMed ID: 17850533
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens.
Lamont EB; Lan L
Med Care; 2014 Mar; 52(3):e15-20. PubMed ID: 22410411
[TBL] [Abstract][Full Text] [Related]
11. Provider Differences in Use of Implanted Ports in Older Adults With Cancer.
Lipitz-Snyderman A; Elkin EB; Atoria CL; Sima CS; Epstein AS; Blinder V; Sepkowitz KA; Bach PB
Med Care; 2015 Jul; 53(7):646-52. PubMed ID: 26035043
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of Medicare claims data for estimation of cancer incidence and resection rates among elderly Americans.
Whittle J; Steinberg EP; Anderson GF; Herbert R
Med Care; 1991 Dec; 29(12):1226-36. PubMed ID: 1745080
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
Kearney M; Thokagevistk K; Boutmy E; Bharmal M
J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
[TBL] [Abstract][Full Text] [Related]
14. Linking physician characteristics and medicare claims data: issues in data availability, quality, and measurement.
Baldwin LM; Adamache W; Klabunde CN; Kenward K; Dahlman C; L Warren J
Med Care; 2002 Aug; 40(8 Suppl):IV-82-95. PubMed ID: 12187173
[TBL] [Abstract][Full Text] [Related]
15. The diffusion of docetaxel in patients with metastatic prostate cancer.
Unger JM; Hershman DL; Martin D; Etzioni RB; Barlow WE; LeBlanc M; Ramsey SR
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25540245
[TBL] [Abstract][Full Text] [Related]
16. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
[No Abstract] [Full Text] [Related]
17. The utility of Medicare claims data for measuring cancer stage.
Cooper GS; Yuan Z; Stange KC; Amini SB; Dennis LK; Rimm AA
Med Care; 1999 Jul; 37(7):706-11. PubMed ID: 10424641
[TBL] [Abstract][Full Text] [Related]
18. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment.
Cooper GS; Yuan Z; Stange KC; Dennis LK; Amini SB; Rimm AA
Med Care; 2000 Apr; 38(4):411-21. PubMed ID: 10752973
[TBL] [Abstract][Full Text] [Related]
19. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
[TBL] [Abstract][Full Text] [Related]
20. Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data.
Huepenbecker SP; Zhao H; Sun CC; Fu S; He W; Giordano SH; Meyer LA
JCO Clin Cancer Inform; 2022 Mar; 6():e2100187. PubMed ID: 35297648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
